Pegasys Newswire

Comprehensive Real-Time News Feed for Pegasys.

Results 1 - 20 of 39 in Pegasys

  1. PEGASYS Powers Its Flagship Encoding Software With DivX(R) HEVCRead the original story w/Photo

    Thursday Apr 30 | Digital Video Editing

    NeuLion , Inc. , a leading technology product and service provider that specializes in the digital video broadcasting, distribution and monetization of live and on-demand content to Internet-enabled devices, today announced that its HEVC SDK has been integrated with TMPGEnc Video Mastering Works 6, the latest video encoding software from Japan-based video encoding specialist PEGASYS Inc. By incorporating the DivX HEVC profile, Video Mastering Works 6 can support high-quality creation of HEVC video at up to 4K/Ultra HD resolutions for playback on any DivX Certified device. TMPGEnc Video Mastering Works 6 with DivX HEVC is slated to be available on May 13, 2015 in English, Japanese and German language.

    Comment?

  2. PEGASYS Powers Its Flagship Encoding Software With DivX(R) HEVCRead the original story w/Photo

    Thursday Apr 30 | Market Wire

    NeuLion , Inc. , a leading technology product and service provider that specializes in the digital video broadcasting, distribution and monetization of live and on-demand content to Internet-enabled devices, today announced that its HEVC SDK has been integrated with TMPGEnc Video Mastering Works 6, the latest video encoding software from Japan-based video encoding specialist PEGASYS Inc. By incorporating the DivXA HEVC profile, Video Mastering Works 6 can support high-quality creation of HEVC video at up to 4K/Ultra HD resolutions for playback on any DivX CertifiedA device. TMPGEnc Video Mastering Works 6 with DivX HEVC is slated to be available on May 13, 2015 in English, Japanese and German language.

    Comment?

  3. Roche Holding's (RHHBY) CEO Dr. Severin Schwan on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Wednesday Apr 22 | Seeking Alpha

    ... e first quarter which I'll get more into detail on. The other products, I won't cover in more detail; after this are Pegasys, just to

    Comment?

  4. Roche sales rise, lifted by cancer drugsRead the original story w/Photo

    Wednesday Apr 22 | MarketWatch

    Roche Holding AG said strong growth of its core cancer franchise pushed sales 3% higher in the first quarter, prompting the Swiss drug giant to confirm its guidance for the year and suggest it will raise its dividend. Basel-based Roche said sales rose to 11.83 billion Swiss francs in the quarter ended March 31, beating an analyst forecast of 11.508 billion francs.

    Comment?

  5. Roche's Avastin cancer drug gets European approvalRead the original story w/Photo

    Wednesday Apr 8 | MarketWatch

    European regulators approved Roche Holding AG's Avastin in combination with chemotherapy for treating women with advanced cervical cancer, the Swiss pharmaceutical giant said Wednesday, expanding the range of cancers the drug can be used to treat. Basel-based Roche said the European Commission approved the expanded use of the drug based on a study that showed the combination of Avastin and chemotherapy resulted in patients living almost four months longer than women receiving chemotherapy alone.

    Comment?

  6. The Global Deflationary TsunamiRead the original story w/Photo

    Mar 20, 2015 | Daily Kos

    Every few years an economic event will happen that can be easily seen by everyone except mainstream economists. Today that economic event is a global tidalwave of deflation that is sweeping the globe.

    Comment?

  7. The Global Laboratory Accessories Market Is Expected to Reach $504.7...Read the original story w/Photo

    Mar 16, 2015 | PRWeb

    This report categorizes the global laboratory accessories market on the basis of products, end users and regions. The key players are "Roche Holding AG , Abbott Laboratories, Inc. , Tecan Group Ltd. , Thermo Fisher Scientific, Inc. , Beckton, Dickinson and Company , Greiner Bio-One GmbH ."

    Comment?

  8. Roche Gets FDA Priority Review for Cancer...Read the original story w/Photo

    Feb 18, 2015 | Wall Street Journal

    Roche Holding AG said Thursday one of its skin cancer treatments had been granted a priority review by the U.S. Food and Drug Administration, cutting the time the drug might take to become available to patients. Basel-based Roche said the FDA would make an accelerated decision on its cobimetinib drug when used with another medication, Zelboraf, to treat a serious form of skin cancer known as BRAF V600 mutation-positive melanoma.

    Comment?

  9. Dividend Growth And Diversification Strategies: Bought 50 Roche At $32.99Read the original story w/Photo

    Feb 18, 2015 | Seeking Alpha

    ... cancer drugs, Perjeta 2012) and Kadclya (2013) are rapidly increasing sales. Both are breast cancer drugs. Sales of Pegasys, an approved treatment for hepatitis B and C, are declining due to competition from new treatments. ( Peginterferon alfa-2a) ...

    Comment?

  10. Roche Says Swiss Franc's Surge May Erode Profit Growth This YearRead the original story

    Jan 28, 2015 | The Washington Post

    Roche Holding AG, the world's largest seller of cancer drugs, said the Swiss franc's surge may strip 9 percentage points from growth in operating profit this year. The currency's strength will probably pare 6 percentage points from sales growth, based on the average exchange rate for January, Chief Financial Officer Alan Hippe said at a press conference in Basel today.

    Comment?

  11. Roche Sees Profit, Sales IncreasingRead the original story w/Photo

    Jan 28, 2015 | Wall Street Journal

    Roche Holding AG posted a 16% drop in annual profit as the Swiss drug maker booked large impairments and restructured its debt, but the company said Wednesday it expects sales and profit to increase this year. Basel-based Roche said sales are expected to grow in low- to mid-single digits in 2015, when stripping out the effect of foreign-currency exchange rate fluctuations.

    Comment?

  12. Apple's Earnings Report Looks Optimistic: MunsterRead the original story w/Photo

    Jan 27, 2015 | Bloomberg

    Jan. 27 -- Piper Jaffray's Gene Munster discusses Apple's fiscal first-quarter profit with Bloomberg's Cory Johnson on "Bloomberg West." Jan. 28 -- Cancer drug Kadcyla "will remain a very important growth driver," said Roche Holding AG Chief Executive Officer Severin Schwan in an interview with Manus Cranny on Bloomberg Television's "Countdown" from Basel.

    Comment?

  13. Roche misses forecasts as costs riseRead the original story w/Photo

    Jan 27, 2015 | MarketWatch

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  14. Roche Profit Misses ForecastsRead the original story w/Photo

    Jan 27, 2015 | Wall Street Journal

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  15. Roche Earnings Preview: Oncology Drugs And Tamiflu Will Help The Revenue GrowthRead the original story w/Photo

    Jan 27, 2015 | Forbes.com

    ... franchise saw strong growth of more than 20% globally, which essentially offset the decline in sales of Xeloda and Pegasys. The monthly sales data from drug retail chains such as Walgreen's suggests that Tamiflu is seeing a strong uptick in sales, ...

    Comment?

  16. Roche Holding acquiring majority stake in US firm Foundation MedicineRead the original story w/Photo

    Jan 12, 2015 | Big News Network.com

    Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news. With a traditional newspaper format, more than 100 sites were established each with a newspaper-type name to cover the highest-ranked regions, countries, cities and states.

    Comment?

  17. Roche invests $1B in U.S. genomics firmRead the original story w/Photo

    Jan 12, 2015 | USA Today

    Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company. Roche said Roche invests $1B in U.S. genomics firm Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company.

    Comment?

  18. Roche to buy $1B stake in genomics companyRead the original story w/Photo

    Jan 12, 2015 | Salt Lake Tribune

    San Francisco a Roche Holding plans to pay more than $1 billion for a majority stake in Foundation Medicine Inc. to get access to genomic tests for screening tumors and to develop a new generation of treatments for fighting cancer. Roche will buy 5 million new shares of Cambridge, Mass.-based Foundation for $50 each and make an offer to purchase stock from existing investors for the same price to take its stake to as much as 56 percent, the companies said in a statement Monday.

    Comment?

  19. Roche to buy majority stake in FoundationRead the original story w/Photo

    Jan 12, 2015 | RTE.ie

    Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, it said today. This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.

    Comment?

  20. Roche To Buy Majority Stake In Foundation For Up To $1.18BRead the original story w/Photo

    Jan 12, 2015 | MSN Money

    Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalized cancer treatments. This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.

    Comment?